December 19th 2023
Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.
January 16th 2024
A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.
Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.
A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.
January 29th 2024
Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.
Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.
January 30th 2024
Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.
Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.
February 6th 2024
Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.
Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.
February 13th 2024
Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.
A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.
February 20th 2024
With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.
Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.
February 27th 2024
Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.